【Case Study】New Approach Methods NAMs
Learn more about our NAMs platform 2D vs 3D hepatocyte model for acetaminophen-induced toxicity A 2D HepG2 culture and 3D HepG2 spheroid system can be used to evaluate acetaminophen-induced toxicity with image-based analysis and viability readouts, illustrating how 3D systems can support longer-term, repetitive exposure designs. Cytokine Release Assay (CRA) for immune activation risk Medicilon […]
AACR 2026
Friday, April 17, 2026,
to Wednesday, April 25, 2026
【Case Study】Route, Solid-State, and Impurity Optimization (Small-Molecule API)
Learn more about our CMC Capability Route, Solid-State, and Impurity Optimization (Small-Molecule API) Program Type: Small-molecule APICMC Focus: Route optimization, solid-state control, impurity management Overview In a separate small-molecule program, Medicilon re-engineered the API synthetic route and solid form strategy to significantly improve manufacturability, safety, and analytical control. The work integrated process chemistry, solid-state science, […]
【Case Study】IND Completion in 12 Months (Small-Molecule NCE)
Learn more about our CMC Capability IND Completion in 12 Months (Small-Molecule NCE) Program Type: Small-molecule New Chemical Entity (NCE)Scope: End-to-end CMC (API process development, analytics, GMP manufacturing, regulatory documentation)Outcome: IND approval achieved ~12 months from contract signing Project Overview Medicilon supported a small-molecule NCE program with fully integrated CMC services, enabling IND approval within […]
DDC 2026
Monday, April 14, 2026,
to Thursday, April 16, 2026
Boston Non-Tumor Models Innovation
Learn more about our Non Tumor Model 1. Imiquimod (IMQ) Induced Psoriasis model Imiquimod (IMQ) Induced Psoriasis model. Female Balb/c mice (9 weeks old) were treated topically with imiquimod (IMQ) on the ear and dorsal skin for seven consecutive days (A). Psoriasis Area and Severity Index (PASI) (B), dorsal skin thickness change (%) (C), and […]
【White Paper】Navigating the DMPK Gauntlet: A Strategic Analysis of the Interconnected Challenges Shaping the Future of Drug Development
1.0 Executive Summary & Introduction The Drug Metabolism and Pharmacokinetics (DMPK) landscape is at a critical inflection point, shaped by the convergence of four powerful and interconnected forces: scientific complexity, technological disruption, regulatory and geopolitical upheaval, and intense business pressures. The traditional paradigms that once guided preclinical development are no longer sufficient. The rise of […]
【White Paper】Patient-Derived Xenograft Organoids: Advancements and Applications in Precision Oncology
Download our PDX Model poster presented at AACR 2025 1. Background of PDX-Derived Organoids 1.1 Historical evolution Patient-derived xenograft (PDX) models, pioneered in the 1960s by Rygaard and Poulsen, marked a significant advancement in oncology by preserving human tumor genetics in immunodeficient mice [1]. These models facilitated in vivo drug resistance studies but were hindered […]
【Blog】PDX-Derived Organoids: How This Mini-Tumor Transforming Cancer Research?
Imagine if we could grow tiny versions of a patient’s tumor in the lab, acting almost exactly like the real thing. PDXOs, the lab-growing 3D models, are not just cool science, they are changing how we discover and test disease treatment. Download our PDX Model poster presented at AACR 2025 So, what exactly are PDXOs? […]
Boston Innovation Meets ADME Precision
Smarter ADME Screening. Flexible Bundle. Greater Confidence. Flexible Screening Panels That Evolve With Your Pipeline. We get it – early discovery is fast-moving and complex. That’s why our bundled in vitro ADME panels are designed for your workflow, whether you choose one, two, or a full suite. Speed, Clarity, and Tailored Flexibility. and we are […]
